Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01856153
Other study ID # 2013-044
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 1, 2013
Est. completion date April 1, 2014

Study information

Verified date July 2021
Source Clinical Nutrition Research Center, Illinois Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary objective is to determine if the efficacy of strawberries delivering polyphenols to prevent metabolic inflammation will be influenced by timing of consumption relative to meal intake. Secondary objective is to characterize the relative bioavailability and absorption profile of strawberry polyphenols consumed with meal or at alternatives times around a meal (2 hours before the meal ad 2 hours after the meal). Third objective is to determine the bioavailability/absorption profile of strawberry polyphenols and its relationship with the anti-inflammatory mechanism of action of strawberry constituents.


Description:

This study is a randomized, single blinded, 3 -arm, within-subjects, placebo-controlled, design utilizing a multiple sampling, and repeated measures paradigm to evaluate timing influence of consumption of strawberry-anthocyanin-associated acute effect on inflammatory markers. A planned sample size of 18 will be recruited into the study. This study will require one initial screening visit, one pre-study visit, and 3 study visits. The study will take 4-5 weeks per subject to complete. The initial screening visit will provide subject informed consent document and determine subject eligibility through height and weight measurements, vital signs, blood glucose test (finger prick), and completion of a survey related to general eating, health, and exercise habits. If willing and eligible to participate, a 3-day food record (2 weekdays and 1 weekend day) will be instructed at initial screening visit and collected at a pre-study visit to assess subjects' baseline dietary intake pattern. After reviewing baseline food records, subjects will be instructed to avoid any berry products throughout the study and follow a strictly limited polyphenolic diet for 3 days prior to the study visit, while maintaining their usual diet pattern and physical activity. Prior each study visit, a dinner meal will be provided the day before the study visit to control the second meal effect from the food and beverage intake of the night before the study visit. Subject will arrive at the study visits fasted for at least 10 hours, well hydrated and rested. Each study visit will require blood draws throughout the visit. After pre-study procedures (height, weight, waist circumferences, vital sign, and blood glucose measurements) , a registered nurse will place a catheter in subject's arm for the purpose of multiple blood sample collections and take the initial blood draw at fasting. Thereafter, blood sample collection will occur every 1 hour for the next 10 hours. During each study visit, subject will drink one of 3 drinks at fasting (right after fasting blood draw), 2nd drink with the breakfast meal (2 hrs after fasting blood draw) and the 3rd drink at 2 hours after the breakfast meal (4 hrs after fasting blood draw), based on randomization (1 strawberry-containing beverage and 2 identical placebo beverages). The sequences of receiving the beverage treatments at each visit will be randomized to one of three: strawberry-placebo-placebo, placebo-strawberry-placebo, or placebo-placebo-strawberry. Premenopausal female subjects will be studied during the follicular phase of their menstrual cycle because food intake tends to be more stable during the follicular phase (days 1-13) than during the luteal phase (days 14-28) when the rise in progesterone levels decrease satiety often resulting in increased intake.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date April 1, 2014
Est. primary completion date April 1, 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - 18 years of age and older - Body Mass Index (BMI) range from 25 to 29.9 kg/m2; exception BMI 23 to 27.4 kg/m2 for Asian population - Nonsmoker - No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease - Not taking any medications that would interfere with outcomes of the study, i.e. lipid lowering medications, anti-inflammatory drugs, or dietary supplements. - Able to provide informed consent - Able to comply and perform the procedures requested by the protocol - Weight stable: not gained or lost weight +/- 5 kg in previous 3 months Exclusion Criteria: - Men and women who smoke - Past smokers: abstinence for minimum 2 years - Men and women with known or suspected food intolerance, allergies or hypersensitivity - Men and women known to have/diagnosed with diabetes mellitus - Men and women who have fasting blood glucose concentrations > 125mg/dL - Men and women who have uncontrolled blood pressure >140 mmHg/90 mmHg - Men and women with documented vascular disease, e.g., heart failure, myocardial infarction, stroke, angina, related surgeries. - Men and women with cancer other than non-melanoma skin cancer in previous 5 years. - Women who are known to be pregnant or who are intending to become pregnant over the course of the study - Women who are lactating - Taking medication or dietary supplements that may interfere with the outcomes of the study; e.g., antioxidant supplement, anti-inflammation, lipid lowering medication. Subjects may choose to go off dietary supplements (requires 30 days washout). - Men and women who have donated blood within 3 months of the screening visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months. - Men and women who are vegans - Substance (alcohol or drug) abuse within the last 2 years. - Excessive coffee and tea consumers (> 4 cups/d) - Men and women who do excessive exercise regularly or athlete - Unstable weight: gained or lost weight +/- 5 kg in previous 3 months - Women who are taking hormonal contraceptive

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Before meal

With Meal

After meal


Locations

Country Name City State
United States Clinical Nutrition Research Center Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Clinical Nutrition Research Center, Illinois Institute of Technology California Strawberry Commission

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Changes in oxidative stress markers over 10 hours after strawberry beverage consumption at different time points. The timing influence of strawberry consumption on bioavailability of strawberry polyphenols and oxidative stress (oxidized LDL) in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal). 10 hours
Other Changes in metabolic markers over 10 hours after strawberry beverage consumption at different time points. The timing influence of strawberry consumption on bioavailability of strawberry polyphenols and metabolic markers (triglyceride, total cholesterol,ApoB, and insulin) in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal). 10 hours
Primary Changes in plasma polyphenol concentrations over 10 hours after strawberry beverage consumption at different time points. The timing influence of strawberry consumption on bioavailability of strawberry polyphenols in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal). 10 hours
Secondary Changes in inflammation markers over 10 hours after strawberry beverage consumption at different time points. The timing influence of strawberry consumption on inflammation markers in relative to meal intake (2 hours before a meal, with a meal, and 2 hours after a meal). 10 hours
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1